ProQR Therapeutics NV (PRQR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ProQR Therapeutics NV (PRQR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8266
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber’s congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It develops novel investigational drug called QR-421 for the treatment of usher syndrome, fuchs endothelial corneal dystrophy, dystrophic epidermolysis bullosa, alzheimer’s disease, central nervous system and neuromuscular diseases. The company also offers clinical trial services. It operates through its laboratory and offices located in Leiden. It operates offices in the US and the Netherlands. ProQR is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NV (PRQR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11
Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 13
Licensing Agreements 14
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14
ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15
ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16
ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17
ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18
Equity Offering 19
ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19
Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21
Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22
Amylon Therapeutics Spin Out from ProQR Therapeutics 23
ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24
ProQR Therapeutics Raises USD112 Million in IPO 25
ProQR Therapeutics NV – Key Competitors 27
ProQR Therapeutics NV – Key Employees 28
ProQR Therapeutics NV – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Strategy And Business Planning 30
Sep 12, 2017: ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics 30
Financial Announcements 31
Aug 08, 2018: ProQR announces financial results for the second quarter of 2018 31
May 09, 2018: ProQR Announces Results for the First Quarter of 2018 32
Feb 28, 2018: ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update 34
Nov 20, 2017: ProQR Announces Results for the Third Quarter of 2017 37
Aug 16, 2017: ProQR Announces Results for the Second Quarter of 2017 39
May 17, 2017: ProQR Announces Results for the First Quarter of 2017 41
Feb 28, 2017: ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update 43
Corporate Communications 46
May 23, 2018: ProQR Appoints Yi-Tao Yu to Its Scientific Advisory Board 46
Nov 09, 2017: ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board 47
Oct 26, 2017: ProQR Announces Management Change and Key Promotions 48
Aug 28, 2017: ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong 49
Mar 27, 2017: ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer 50
Product News 51
Jun 15, 2017: ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer, a novel proprietary RNA Technology 51
05/01/2017: ProQR to Present Data on QRX-411 at ARVO 53
05/01/2017: ProQR to Present Data on QRX-421 at ARVO 54
Product Approvals 55
Sep 05, 2017: ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 55
Jul 05, 2017: ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 56
Clinical Trials 57
Oct 24, 2017: ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference 57
Sep 25, 2017: ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis 58
Aug 29, 2017: ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial 60
Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Deals By Therapy Area, 2012 to YTD 2018 9
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11
Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 13
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14
ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15
ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16
ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17
ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18
ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19
Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21
Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22
Amylon Therapeutics Spin Out from ProQR Therapeutics 23
ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24
ProQR Therapeutics Raises USD112 Million in IPO 25
ProQR Therapeutics NV, Key Competitors 27
ProQR Therapeutics NV, Key Employees 28
ProQR Therapeutics NV, Other Locations 29
ProQR Therapeutics NV, Subsidiaries 29

List of Figures
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ProQR Therapeutics NV (PRQR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Datalogic SpA (DAL):企業の財務・戦略的SWOT分析
    Datalogic SpA (DAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Canadian National Railway Co:戦略・SWOT・企業財務分析
    Canadian National Railway Co - Strategy, SWOT and Corporate Finance Report Summary Canadian National Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • BrightSpring Health Services:企業の戦略的SWOT分析
    BrightSpring Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Taita Chemical Co Ltd (1309):企業の財務・戦略的SWOT分析
    Taita Chemical Co Ltd (1309) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cree, Inc.:企業の戦略・SWOT・財務分析
    Cree, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cree, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary BerGenBio ASA (BerGenBio) is a clinical-stage biopharmaceutical company that develops drugs to treat multiple aggressive cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 is an AXL kinase inhibitor which …
  • Petroleos Mexicanos:企業の戦略的SWOT分析
    Petroleos Mexicanos - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Duskin Co Ltd:企業の戦略・SWOT・財務情報
    Duskin Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Duskin Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company’s services include marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data analy …
  • Western Gas Partners, LP:企業のM&A・事業提携・投資動向
    Western Gas Partners, LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Western Gas Partners, LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • AMETEK Inc (AME):企業の財務・戦略的SWOT分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturer. The company manufactures electronic instruments and electromechanical devices. Its product portfolio includes medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys a …
  • Rohto Pharmaceutical Co Ltd (4527):企業の財務・戦略的SWOT分析
    Rohto Pharmaceutical Co Ltd (4527) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Alliqua BioMedical Inc (ALQA):医療機器:M&Aディール及び事業提携情報
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc, is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s products comprise ultrasound healing therapy, human biologics, antimicrobial protecti …
  • Rizal Commercial Banking Corp (RCB):企業の財務・戦略的SWOT分析
    Summary Rizal Commercial Banking Corp (RCBC) is a commercial and financial banking service provider that offers corporate, commercial, and consumer banking, cash management, treasury, and remittance products and services. The company’s electronic banking services include mobile banking, internet ban …
  • Mauna Kea Technologies SAS (MKEA):企業の財務・戦略的SWOT分析
    Summary Mauna Kea Technologies SAS (MKT) is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides confocal laser endomicroscopy platform. MKT’s cellvizio is an endomicro …
  • Mapletree Investments Pte Ltd:企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Marquard & Bahls AG:企業の戦略・SWOT・財務分析
    Marquard & Bahls AG - Strategy, SWOT and Corporate Finance Report Summary Marquard & Bahls AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Caltex Australia Ltd (CTX)-石油・ガス分野:企業M&A・提携分析
    Summary Caltex Australia Limited (Caltex) is a transport fuel supplier and convenience retailer. It is the parent company of Caltex group. The company purchases, refines, distributes and markets petroleum products. It owns and operates refinery, convenience stores, road tankers, storage terminals, s …
  • Immunomedics Inc (IMMU):医療機器:M&Aディール及び事業提携情報
    Summary Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technol …
  • Sonova Holding AG:企業の戦略・SWOT・財務分析
    Sonova Holding AG - Strategy, SWOT and Corporate Finance Report Summary Sonova Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆